

1 **Title - Investigating immune amnesia after measles virus**
2 **infection in two West African countries: A study protocol**
3 **Short Title - Investigating immune amnesia in two West**
4 **African countries**

5
6 **Authors**

7 Karine Fouth Tchou¹, Renée Ridzon¹, Mory Cherif Haidara², Djeneba Dabita³, Esther Akpa¹, Daouda
8 Camara², David Vallée⁴, Mariam Coulibaly³, Sekou Camara², Jamila Aboulhab¹, Mahamadou Diakité³,
9 Bassirou Diarra³, Samba Diarra³, Ilo Dicko³, Alyson Francis⁵, Cécé Francis Kolié², Michel Koropogui², Caeul
10 Lim⁴, Seydou Samaké³, Sally Hunsberger¹, Moussa Sidibé², Ray Y. Chen¹, Issa Konate³, Seydou Doumbia³,
11 Abdoul Habib Beavogui², and Kathryn Shaw-Saliba¹

12

¹Division of Clinical Research, NIAID/NIH, Rockville, Maryland, USA

²Centre National de Formation et de Recherche en Santé Rurale (CNFRSR) de Maferinyah, Conkary,
Guinea

³University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako,
Bamako, Mali

⁴Clinical Monitoring Research Program Directorate (CMRPD), Frederick National Laboratory for Cancer
Research, Frederick, Maryland, USA

⁵Systemex, Inc, Rockville, Maryland, USA

13 **Data availability**

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

14 This article does not report any data and the data availability policy is not applicable.

15 **Abstract**

16 “Investigation of Immune Amnesia Following Measles Infection in Select African Regions”
17 (ClinicalTrials.gov Identifier: NCT06153979) is a prospective, observational, longitudinal study being
18 conducted in two West African countries, Guinea, and Mali. The overall goal is to investigate the impact
19 of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to
20 subsequent illness. A total of 256 children aged 1 to 15 years are being enrolled into one of two study
21 arms: those with acute MeV infection (cases) and without (controls). Acute MeV is confirmed by RT-PCR
22 testing on upper respiratory specimens or IgM detection on blood samples at screening. Blood samples
23 are collected at multiple time points at screening (Day 0), at an optional visit to repeat IgM serology for
24 inconclusive or negative Day 0 results (Day 7-10), and during follow-up visits on Day 14, Week 13, and
25 Week 52. These blood samples will be tested to evaluate both humoral and cellular immune responses to
26 endemic pathogens to measure variations in antibody diversity and antibody secreting cells (ASCs). To
27 explore how recent MeV infection may affect the child’s ability to respond to a controlled immune
28 stimulus, all participants will receive rabies vaccine pre-exposure prophylaxis (PrEP) using Verorab
29 inactivated rabies vaccine. Three doses of 0.5 ml of VERORAB vaccine are administered on Days 0, 7, and
30 28. Biological samples will be collected after vaccination to assess if the rabies vaccine response differs:
31 1) between cases and controls, and 2) based on the timing of the rabies vaccination after acute measles
32 infection. In addition, the study team will collect information on healthcare encounters during the year-
33 long follow-up will be collected to determine if there is a difference in the number of encounters by study
34 group. The findings of this study will further the understanding of the MeV immune amnesia phenotype.

35

36 Introduction

37 Measles virus (MeV) infection is a major cause of death globally for children under five years of age [1-3].

38 There are reports of increases in cases in many countries, including in West Africa [4, 5]. The Expanded

39 Program on Immunization in Guinea and Mali calls for two doses of measles vaccine starting at 9 months

40 [6, 7]. According to WHO/UNICEF national immunization coverage estimates for the African region in

41 2022, 69% of children received the first measles vaccine and 45% received the second [6]. The rates in

42 Mali were very close to these averages, at 70% for the first dose and 44% for the second dose, but Guinea

43 lagged farther behind, at 47% and 3%, respectively [8]. These rates are far below the 92-95% level

44 required for herd immunity and control of community transmission of measles [9]. This is largely due to

45 the fact that, over the past decade, West Africa has experienced measles outbreaks following large-scale

46 public health emergencies, such as the Ebola epidemic and the COVID-19 pandemic, which have disrupted

47 global routine childhood vaccine coverage [10-12]. Armed conflict has also disrupted routine vaccinations

48 in many countries, resulting in a disproportionate number of cases of vaccine preventable diseases,

49 including measles [13, 14]. Finally, some vaccination campaigns may have used vaccines where

50 appropriate storage conditions were not maintained due to a lack of available resources or equipment.

51 Thus, the presence of global measles outbreaks underscores the importance of studies that will contribute

52 to a better understanding of the effect of MeV infection on morbidity and mortality.

53 MeV infection not only directly causes morbidity but is also associated with increased susceptibility to

54 other infections and/or increased hospitalizations [15-19]. Measles vaccination has been associated

55 with larger reductions in morbidity and mortality than would be expected if caused by acute MeV

56 infection alone [19-24]. While there is a strong immune response to MeV infection that confers life-long

57 immunity to MeV there is some evidence of a loss of existing immunity to other pathogens. This

58 phenomenon, known as “immune amnesia” [25], is associated with a loss of memory B cells and
59 reduced antibody repertoires from previous infections and vaccinations [26, 27]. MeV-induced immune
60 amnesia has been characterized in animal studies with ferrets and rhesus macaques and has also been
61 examined in European populations [26, 28, 29]. Given the current outbreaks of measles in West Africa,
62 this study aims to determine whether measles-induced immune amnesia occurs in African regions and
63 affects immune responses to endemic pathogens such as *Mycobacteria tuberculosis*, *Plasmodium*
64 species, and arthropod-borne viruses (e.g., yellow fever virus or dengue). The hypothesis of this study is
65 that acute MeV infection induces a loss of pre-existing immunity to pathogens prevalent in select African
66 regions. Compared to those who do not have acute MeV infection, acute MeV infection will result in 1) A
67 loss of antibody diversity from previous infections and/or vaccinations compared to baseline; 2) Altered
68 immune response to a controlled immune stimulus (rabies vaccination) given at two different
69 timepoints; 3) Increased incidence of illnesses or healthcare encounters in the year following acute MeV
70 infection.

71
72 The data gathered in this study will better characterize the effect and mechanism of measles-induced
73 immune amnesia in children. The design of this study is described.

74 **Material and methods**

75 **Ethical statement**

76 National Institute of Allergy and Infectious Diseases (NIAID) is the sponsor of the study. The main
77 protocol and each of the site-specific appendices received approval from local ethics committees and/or
78 health authorities prior to study implementation including the University of Sciences, Techniques and
79 Technologies Bamako Mali #2023/210/CE/USTTB -Sept 18, 2023, and Guinea CNERS # 145/CNERS/23 -

80 Sept 8, 2023. Prior to initiation of any study procedures, all study participants must have an informed
81 consent signed by a parent or guardian, and an assent as applicable, in a language they understand.

82 **Clinical study design**

83 Study Overview: “Immune Amnesia Following Measles Infection in Select African Regions”
84 (ClinicalTrials.gov Identifier: NCT06153979), is a prospective, observational, longitudinal study being
85 conducted in West Africa to investigate the effects of MeV infection on pre-existing immunity, vaccine
86 response, and susceptibility to subsequent illnesses. A total of 256 children are being enrolled into 1 of 2
87 arms: acute MeV infection (cases) or no acute MeV infection (controls) as assessed using RT-PCR on
88 upper respiratory specimens and IgM on blood samples. Blood samples are collected at Screening (Day
89 0), optional repeat IgM serology for inconclusive or negative Day 0 results (Day 7-10), and at follow-up
90 visits (Day 14, Week 13, and Week 52). The blood samples will be tested for humoral and cellular
91 immune responses to endemic pathogens to determine changes in antibody diversity and antibody
92 secreting cells (ASCs).

93
94 To explore how recent MeV infection affects the ability to respond to an immune stimulus, participants
95 will receive rabies vaccine pre-exposure prophylaxis (PrEP) with Verorab inactivated rabies vaccine
96 (Sanofi) as part of the study. Rabies vaccine is an immunogen to which most participants have not been
97 exposed and thus can be used to measure the immune response to a newly encountered antigenic
98 stimulus. Additionally, as rabies is estimated to cause 59,000 human deaths annually worldwide with the
99 highest mortality in Africa [30, 31], the provision of rabies PrEP is a benefit to participants in the study
100 [32]. All children in each arm will receive rabies vaccination (3-dose series at Days 1, 7 and 28 given as
101 PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment. WHO now
102 recommends a 2-dose PrEP schedule [31]. However, we decided to use the older 3-dose schedule from

103 the Verorab package insert (<https://www.medicines.org.uk/emc/files/pil.15572.pdf>) to give the acute
104 measles cohort children the best chance of developing an immune response in the event of persisting
105 immune amnesia. Biological samples will be collected after vaccination to assess if the immune stimulus
106 (rabies vaccine) response differs: 1) between children with and without MeV infection, and 2) based on
107 the timing of the receipt of the rabies vaccine. A participant who is potentially exposed to rabies during
108 study participation will be provided rabies post exposure prophylaxis (PEP) with Verorab vaccine, with or
109 without human rabies immune globulin, based on published recommendations [32]. The study schedule
110 is depicted in Figure 1.

111 **Fig 1: Study Schedule**

112 Abbreviations: AE, adverse event; HIV, human immunodeficiency virus; Ig, immunoglobulin; MUAC, mid-
113 upper arm circumference; NP, nasopharyngeal; OP, oropharyngeal; PCR, polymerase chain reaction.

114 (X) = Each participant will receive only one 3-dose series of rabies vaccine according to randomization to
115 early group (vaccination at Visits 2, 3, and 4) or late group (vaccination at Visits 8, 9, and 10).

116 ^a EARLY rabies vaccination: Only participants randomized to EARLY rabies vaccine attend Visits 2, 3, 4.

117 Visit 2 occurs 8 weeks after Day 0; Visit 3 occurs 7 days after Visit 2; Visit 4 occurs 21 to 28 days after

118 Visit 2 AND at least 14 days after Visit 3.

119 ^b LATE rabies vaccination: Only participants randomized to LATE rabies vaccine attend Visits 8, 9, 10. Visit

120 8 occurs 47 weeks after Day 0; Visit 9 occurs 7 days after Visit 8; Visit 10 occurs 21 to 28 days after Visit

121 8 AND at least 14 days after Visit 9.

122 ^c Day 0 is defined as the day screening occurs and the first research blood sample is collected.

123 Inclusion/exclusion criteria evaluation for enrollment will be completed when PCR and measles

124 IgG/IgM and HIV results are available, generally by Day 14. All potential participants (or

125 guardian/parent) will be informed of eligibility status by a designated study staff by phone, if possible,

126 prior to the Day 14 scheduled study visit or at the Day 14 scheduled study visit. Ineligible participants

127 may be invited to the site to discuss test results and referral for measles vaccination if serum IgG and
128 IgM are both negative.

129 ^d Vital signs include temperature, heart rate, and respiratory rate; may be obtained prior to rabies
130 vaccine administration, if clinically indicated.

131 ^e MUAC in children 12 to 59 months old.

132 ^f HIV testing for children younger than 24 months will be performed via PCR and repeated with Rapid
133 Diagnostic Test (RDT) at end of study to adhere to national guidelines; HIV RDT will be performed at
134 screening for participants 24 months and older and will not be repeated at end of study.

135 ^g HIV and measles serum IgM/IgG results must be reviewed for eligibility confirmation prior to Day 14.

136 ^h Blood will be collected for hemoglobin test via finger and/or heel stick. Hemoglobin and urine
137 pregnancy rapid test results must be reviewed prior to venous blood sample collection.

138 ⁱ Females of child-bearing potential must have a negative pregnancy test prior to enrollment and each
139 rabies vaccine administration.

140 ^j Measles vaccination to be administered to control participants (through the study or referral to
141 Ministry of Health vaccination program) if serum measles IgG and IgM are both negative.

142 ^k 5 mL is the maximum volume that will be obtained at each blood draw.

143 ^l Vitamin A will be administered at D0 to all participants with clinical measles per WHO guidelines: 2 oral
144 doses of 200,000 IU given 24 hours apart. The first dose will be administered at the study site and the
145 second will be provided to the parent to be administered 24 hours later.

146

147 The study team will collect, to the extent possible, information on healthcare encounters for evaluation
148 and treatment of illness during the year-long follow-up to determine if there is a difference in the
149 number of encounters by study group.

150 The study objectives and endpoints are shown in Table 1.

151 **Table 1: Study objectives and endpoints**

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
Primary		
To determine if MeV infection induces a loss of pre-existing immunity (immune amnesia) to endemic pathogens at Week 13 after baseline in children in select African regions.	Mean change in a panel of antibody levels over 13 weeks as measured by multiplex serological methods (e.g., Molecular Indexing of Proteins by Self-Assembly (MIPSA) with an updated VirScan library and additional libraries with endemic bacteria and parasite) and targeted ELISAs for confirmation.	These methods detect antibodies against multiple diverse pathogens and epitopes and assess both neutralizing and non-neutralizing antibodies.
To determine the effect of MeV infection on immune response to a controlled immune stimulus (rabies vaccination) at early and late timepoints post-infection.	Geometric mean RVNA titer 5-6 weeks after the first rabies vaccine dose.	These tests will measure the immune response and functionality of antibodies raised against the rabies vaccine.
	Proportion of subjects with an RVNA titer \geq lower limit of quantification 5-6 weeks after the first rabies vaccine dose. Proportion of subjects with rabies virus neutralizing antibodies (RVNA)	

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
	<p>titer \geq 0.5 International Units per milliliter (IU/mL) as measured by rapid fluorescent focus inhibition test 14 days after the last PrEP regimen vaccination.</p>	
Secondary		
<p>To determine if there is an increase in healthcare system encounters in the year following enrollment in children with recent MeV infection compared to those without recent MeV infection.</p>	<p>Mean number of non-study sick visit healthcare system encounters during the 1-year follow-up.</p>	<p>Visits to the healthcare system for sick visits in the year following enrollment in children with recent MeV infection will help determine the clinical impact of the immune amnesia in an objective manner.</p>
<p>To determine if MeV infection induces a loss of pre-existing immunity (immune amnesia) to endemic pathogens at Week 52 after baseline in children in select African regions.</p>	<p>Mean change in a panel of antibody levels over 52 weeks as measured by multiplex serological methods (e.g., MIPSAs with an updated VirScan library and additional libraries with endemic bacteria and parasite) and targeted ELISAs for confirmation.</p>	<p>These methods detect antibodies against multiple diverse pathogens and epitopes. These represent the spectrum of both neutralizing and non-neutralizing antibodies.</p>

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
Exploratory		
<p>To assess the appearance and continued production of B and T cells, especially ASCs from peripheral blood mononuclear cells (PBMCs) in circulation following MeV infection in children 1-15 years old in a subset of participants, depending on availability of collected blood samples.</p>	<p>Mean change in cell number and functionality from baseline to 14 days.</p>	<p>Assessing the number and functionality of the B and T cells including ASCs will give insight into the impact of MeV on B cell development and humoral immunity.</p>
<p>To attempt to identify the etiology of illness in children who present with signs and symptoms consistent with measles and are screened but not enrolled due to negative measles PCR and IgM.</p>	<p>Unbiased next generation sequencing for pathogen discovery directly from the oropharyngeal (OP)/nasopharyngeal (NP) swab.</p>	<p>This may identify other pathogens that may mimic the clinical presentation of MeV in children who have symptoms but test negative.</p>
<p>To identify the genotypes of MeV collected in the study.</p>	<p>Next generation sequencing or targeted Sanger sequencing directly from the OP/NP.</p>	<p>This will allow identification of different genotypes of MeV in the countries enrolling participants.</p>

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
<p>To characterize the phenotype of the rash and/or Koplik spots in children who present with signs and symptoms consistent with measles who test positive for measles (polymerase chain reaction [PCR] and/or IgM positive) and who test negative for measles (PCR and IgM negative).</p>	<p>Differences in rash patterns/presentation in children who test positive versus those who test negative for measles based on analysis of photographs.</p>	<p>This will allow for a comparison of rash and/or Koplik spot presentation in potential cases that end up testing positive or negative for measles in the laboratory. This will complement the exploratory objective of identifying the etiology via unbiased next general sequencing in the participants who test negative for measles. In addition, we can contribute images of measles rash on dark skinned children and Koplik spots to the medical literature.</p>

152 **Eligibility**

153 The study inclusion and exclusion criteria are shown in Table 2. Children aged 1-15 years who are eligible
 154 after initial screening are enrolled in Group 1 of children with acute MeV infection (cases) or Group 2 of
 155 children OP eligible for the study and will be referred for care. An upper respiratory specimen (O

156 oropharyngeal (OP)/nasopharyngeal (NP)) for MeV PCR and plasma for measles IgM/IgG serology are
 157 collected. Plasma and PBMCs are also collected at screening for research assays. PBMCs will only be
 158 collected in Mali due to operational constraints and lack of dry ice in Guinea. Anyone suspected of
 159 having measles at the time of screening will be treated with Vitamin A 200,000 IU by mouth per day for
 160 2 days, as recommended by the World Health Organization [33].

161 **Table 2: Study Inclusion and Exclusion Criteria**

Inclusion Criteria	Exclusion Criteria
<ol style="list-style-type: none"> 1. Aged 1 to 15 years. 2. Ability of the participant’s legal or culturally acceptable representative to provide informed consent. 3. Ability to give assent, as appropriate. 4. Stated willingness of parent/guardian and participant as appropriate, to comply with all study procedures. 5. Willingness to receive rabies vaccine. 6. Meet the criteria for assignment to Group 1 or Group 2, as follows: <ol style="list-style-type: none"> a. Group 1, cases (acute MeV infection): <ul style="list-style-type: none"> • Clinical signs and symptoms suggestive of acute MeV 	<ol style="list-style-type: none"> 1. HIV infection or any other immunosuppressive condition or medications. 2. Pregnant or lactating. 3. History of prior measles or immunologic evidence of prior measles in the absence of prior measles vaccination. 4. Severe anemia, defined as hemoglobin less than 8 g/dL. 5. Any acute or chronic condition which, in the opinion of the investigator, constitutes a contraindication to participation in this study.

<p>infection (Koplik spots or skin rash) AND</p> <ul style="list-style-type: none">• Laboratory confirmed measles:<ul style="list-style-type: none">○ Upper respiratory specimen (swab) PCR for measles positive. <p>OR</p> <ul style="list-style-type: none">○ Serum IgM for measles positive. <p>b. Group 2, controls (no acute MeV infection):</p> <ul style="list-style-type: none">• No clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND• Upper respiratory specimen (swab) PCR negative for MeV AND• Serum measles IgM negative AND• Serum measles IgG positive and previously vaccinated for measles (2nd dose will be	
--	--

offered if appropriate). If serum measles IgG is negative, participant must be willing to be vaccinated regardless of prior measles vaccine history to meet this criterion.	
--	--

162

163 **Study visits according to initial protocol**

164 A schematic depiction of the study visit timing is shown in fig 1. During Visit 0 on Day 0, demographic,
165 medical history, vaccination history and concomitant medication information are collected, and a
166 physical exam is performed. Mid upper arm circumference is obtained in children ≤ 59 months. Due to
167 the turnaround time for the MeV PCR and measles IgM/IgG in the laboratory, eligibility as a case or
168 control is confirmed at Visit 1 on Day 14. Measles vaccination will be administered to controls who do
169 not have a positive measles IgG at this visit. Once enrolled, participants will be randomized to receive 3
170 doses of rabies vaccine as PrEP early (doses at Weeks 8, 9, 11-12) or late (doses at Weeks 47, 48, 50-51).
171 At Weeks 26 and 39, a healthcare questionnaire will be administered. Windows around study visits are
172 relatively short so that the targeted endpoints can be captured accurately. Visits that occur out of the
173 window periods are permitted under special circumstances, to avoid missed visits. A research blood
174 sample is collected at Days 0 and 14, and Weeks 13 and 52; prior to collection of blood, hemoglobin is
175 checked in all participants via a fingerstick, and a urine pregnancy test is obtained in females starting at
176 their reproductive age. Anyone found to be pregnant is withdrawn from the study. If the hemoglobin is

177 <8 g/dl at the follow up blood draw visits, the participant remains in the study, but a blood sample is not
178 collected.

179 **Fig 2: Study Schematic**

180 ¹Research blood samples

181 ² Measles vaccination in controls if confirmed to have negative serum measles IgG

182 ³ Rabies vaccine Dose 2 is given 7 days +2 days after Dose 1, and Dose 3 is given at Day 21 to Day 28
183 after Dose 1 and at least 14 days after Dose 2

184 ⁴Healthcare utilization assessment

185 **Study sites**

186 This study is being conducted in Guinea and Mali, which were chosen based on measles epidemiology,
187 existing research infrastructure, and ongoing partnerships between their Ministries of Health, and in
188 Mali, the Ministry of Higher Education, and the National Institute of Allergy and Infectious Diseases
189 (NIAID) in the United States.

190 The Partnership for Clinical Research in Guinea (PREGUI) aims to conduct and implement a program of
191 national and international, high-quality research on public health priorities in Guinea, and to build and
192 develop sustainable research capacity. This study is implemented at two sites under PREGUI, both
193 located within treatment centers for diseases with epidemic potential at referral hospitals in Forécariah
194 and Mafèrinyah. These sites receive referrals from surrounding health centers, health posts and
195 communities and are each served by a multidisciplinary team.

196 The University Clinical Research Center (UCRC) is located at the University of Sciences, Techniques, and
197 Technologies of Bamako in Mali. Its mission is to promote clinical research and training at international
198 standards in Mali and within the West Africa region. The UCRC offers competence in clinical research

199 including clinical operations, laboratory diagnosis and exploration of immune function, data
200 management, pharmacy and community engagement. The research team recruits participants from the
201 Commune VI Reference Health Center and the Bakorobabougou Community Health Center, both in
202 Bamako.

203
204 The first participant was enrolled in Guinea in January 2024 and in Mali in February 2024. Additional
205 sites in either country may be opened depending on the enrollment rates and available funding.

206 **Amendment**

207 After screening the first 33 potential participants with suspected measles, laboratory results confirmed
208 measles was present in only 15 (45.5%), showing that the clinical diagnosis does not always match the
209 validated laboratory assay results. Due to concerns that true measles cases were being missed because
210 the IgM test was possibly conducted too early, prior to development of the IgM response but after the
211 viremic period leading to false negative results [\[34-37\]](#), the protocol was amended. Thus, children highly
212 suspected of measles based on their clinical presentation but who tested negative on both PCR and IgM
213 at day 0 may have an optional visit between days 7-10 to retest for measles IgM [\[34-37\]](#). Adding a day
214 7-10 re-test allows more time for the IgM response to develop. Optional photography of participants
215 being screened as potential cases was also added to the protocol. Photographs of the rash in confirmed
216 measles cases will be used to train study staff to improve recognition of acute MeV infection in dark
217 skinned children and serve as an educational tool for the medical community. In screened potential
218 cases who test measles negative, these photos will be coupled with the information gained in the
219 exploratory aim of unbiased sequencing of other pathogens to determine the phenotype of other febrile
220 rash illnesses that may otherwise be clinically diagnosed as measles.

221 **Laboratory and stored specimens**

222 The RNA is extracted from the NP/OP swabs collected in viral transport media (VTM) at screening and
223 tested by RT-PCR for MeV. Remaining VTM samples will be stored for sequencing and genotyping of
224 MeV. Samples from children with signs and symptoms consistent with measles but who test negative
225 are stored and can be examined for other viruses using pathogen discovery sequencing methods.
226 Measles IgG and IgM are measured using an enzyme linked immunoassay on plasma samples. The
227 screening tests used in each country (hemoglobin, pregnancy, measles serology, HIV) all underwent
228 verification prior to study start to ensure the reproducibility and accuracy of the results. Plasma
229 collected at baseline (Visit 0), week 13 (Visit 5) and week 52 (Visit 11) will be tested at a commercial
230 laboratory in the United States to measure antibody binding to epitopes of select viruses, bacteria and
231 parasites using validated multiplex serological methods (e.g., Molecular Indexing of Proteins by Self-
232 Assembly [MIPSA] technology with an updated library and additional libraries with endemic bacteria and
233 parasites) [26, 38]. PBMCs are isolated from blood specimens, stored in liquid nitrogen, and will be
234 analyzed for ASC. Plasma obtained following rabies vaccination will be shipped to a commercial
235 laboratory accredited to perform Rapid Fluorescent Foci Inhibition Test (RFFIT) to ensure neutralizing
236 antibody (RVNA) response to the rabies vaccine and to compare cases to controls and those randomized
237 to early vaccination versus late vaccination. Samples not used for analyses will be stored and managed
238 electronically in the local biorepositories under appropriate temperature with constant monitoring.

239 **Safety reporting and monitoring**

240 Safety reporting and monitoring is done according to national regulatory guidelines and International
241 Council for Harmonisation (ICH). A clinician with appropriate expertise (Principal Investigator
242 [PI]/Designee) will assess adverse event (AE) severity, according to the “Division of AIDS Table for

243 Grading the Severity of Adult and Pediatric Adverse Events”

244 (<https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>) and determine the

245 seriousness, relatedness and expectedness of the event. This may be done in coordination with the

246 sponsor, NIAID. Per study specific standard operating procedure, only AEs related to study procedures

247 will be followed through resolution or until the local investigator judges that the event has stabilized,

248 and no additional follow-up is required. Safety events will be tracked and submitted to the local ethics

249 committees according to each country’s requirements as described in the site-specific appendices. All

250 AEs will be recorded on source documents.

251

252 AEs related to the research procedures and all serious adverse events (SAEs) will be recorded in the

253 research database, except for Grade 1 or 2 AEs that are expected. SAEs and Unanticipated Problems will

254 be reported to Sanofi Pasteur with coded data according to the terms of a confidential Clinical Trials

255 Agreement.

256 **Statistical aspects**

257 The overall sample size of the study is 256 participants, 128 enrolled as cases and 128 as controls. The

258 sample size accounts for a 6.5% rate of dropout from the study and participants who drop out will not

259 be replaced. The sample size is calculated to detect a difference in the RVNA geometric mean titer

260 between the measles cases and controls who were either vaccinated at the early time point or at the late

261 time point). If each vaccination group (early/late) contains 128 participants with 64 cases and 64

262 controls, there will be 90% power to detect a difference of 0.85 between cases and controls under each

263 of the vaccination conditions. There will also be 90% power to detect an interaction between group

264 (measles/controls) and time (early/late) if the effect size is 1.19. The interaction corresponds to showing

265 a different response between cases and controls at early and late rabies vaccine stimulus times. There is

266 90% power to detect standardized mean differences of 1.00 when looking for differences in panels of
267 antibodies between cases and controls in each age group. This calculation controls for multiple
268 comparisons. This effect size was similar to those observed in the paper by Mina et al [26].

269

270 Analysis of the rabies antibody response will be performed using multivariate linear regression on the
271 \log_{10} titer values, including terms for case/control group, early/late vaccine, country and an interaction
272 between group and timing of vaccine. Antibody responses to a panel of antigens will be compared
273 between case/control groups using t-tests on change from baseline. Separate analyses will be
274 performed for 2 age groups (1-5 and 6-15 years). A Bonferroni correction will be used to maintain a 2-
275 sided 0.05 error rate by adjusting for the number of antibodies in the panel. A Poisson analysis will be
276 used to compare the number of encounters with medical providers between groups.

277

278 Control participants who become infected with measles or participants from either group who become
279 pregnant at any time during the study will be censored at the time of infection or pregnancy. A
280 participant who has a potential rabies exposure and receives rabies PEP during the study before s/he is
281 scheduled (randomized) to receive rabies vaccination as PrEP will be excluded from the primary analysis
282 of the rabies vaccine but included in the immune amnesia analysis. Participants who receive at least one
283 dose of rabies PrEP (as randomized) will be analyzed as planned. A Statistical Analysis Plan (SAP) will be
284 prepared for the study before analyses begin.

285 **Study conduct, data management, operational logistics and challenges**

286 The study leadership consists of a core team of research physicians, statisticians, laboratory research
287 scientists, clinical research pharmacist and operational experts from the Division of Clinical Research
288 (DCR) of NIAID and both countries. Both countries have clinical research staff and infrastructure

289 supported by DCR. The study protocol was developed collaboratively. The country teams are responsible
290 for submission for ethical review, continuing review reports, quality management plans, protocol
291 deviations, and SAE reports per country regulations and as requested by NIAID. At all stages, regular
292 teleconferences and visits are held and include study leadership, country scientific/medical laboratory,
293 data management and clinical operations teams, and serve as a forum for information exchange on
294 topics such as recruitment, case adjudication, visit adherence, as well as providing feedback and
295 suggestions on study procedures. A Publication Policy has been developed to guide the drafting and
296 review of all study-related abstracts, presentations, and manuscripts, and a Publication Committee that
297 includes representatives from NIAID and each of the country teams will be formed. For requests for
298 secondary use of biospecimens, the Publication Committee will be approached to approve access to
299 biospecimens. Electronic case report forms (CRFs), core standard operating procedure (SOP) documents
300 and manuals of operation (MOP) were developed along with site-specific documents.

301 The study was designed to use electronic data capture into the Clinical Data Management System
302 (CDMS). Malian staff enter data from study-specific paper source documents. Guinean staff use direct
303 data entry into tablets in an online mode, where the data are saved automatically to the CDMS. If
304 internet connection is temporarily disrupted, the data are captured and uploaded to the CDMS once
305 service is restored. This hybrid approach allows for more flexibility across sites, reduces need for
306 printing CRFs, and requires less transcription of data by the sites. Direct data entry also allows sites to
307 address any queries that arise from programmed data checks at time of entry. The completed data are
308 then reviewed by the central data management team for consistency and accuracy. Randomization is
309 also performed electronically in the CDMS.

310 Specimen kits with standard barcodes were designed for specimen collection. The specimens collected
311 are stored in-country under proper conditions with constant temperature monitoring and documented
312 in an electronic system.

313 A monitoring plan is used for central monitoring, to facilitate compliance with GCP, guidelines and
314 regulations, identify key activities and specify data to be reviewed for the study. Each plan was reviewed
315 by the study teams in Guinea and Mali and the Measles Study protocol team to ensure adherence to the
316 protocol, laboratory, and GCP requirements. In person and virtual trainings on were conducted with the
317 study staff in each country. Refresher trainings are offered as needed.

318 Each country has encountered challenges with study implementation. The Guinean team is working on
319 enhancing its ability to use electronic systems for study documents and sample management, manage a
320 heavy workload for the available laboratory staff, and ensure participants have a good understanding of
321 study processes. The Malian team is working on increasing the number of screened volunteers by
322 involving more community health centers in referring suspected measles cases to the team. Also, to
323 enhance use by community mobilizers and to sensitize community members about the study, flipbooks,
324 a consenting tool depicting the study procedure in easily understood language with images, have been
325 translated into Bambara, the most spoken language in Mali. Because the sites experience power losses
326 that compromise refrigeration, all study vaccines are stored off site where a continuous power supply is
327 assured and transported to the sites as needed. Finally, due to the waxing and waning measles cases in
328 both countries, enrollment is taking longer than expected.

329 **Conclusion**

330 We have designed and launched an international observational study to investigate immune amnesia
331 following MeV infection in Guinea and Mali, which have recurrent measles outbreaks. Despite

332 challenges of collaborative protocol development, operationalization and need for multiple
333 authorizations to import rabies and measles vaccines, the study was successfully initiated in 2024. This
334 effort will add to the literature on measles immune amnesia and response to an immune stimulant by
335 providing data in a population that has not been previously examined and will also provide data on MeV
336 genotypes circulating in these regions. It may also bring insights to other viral causes of the
337 maculopapular rash illness in children. In addition, the photographs of the rash will add to the current
338 literature on measles and other rash illnesses in children with dark skin.
339

340 **Acknowledgements**

341 We thank PREGUI study team members, Centre National de Formation et de Recherche en Santé Rurale
342 de Mafèrinyah, Centres de Santé Amélioré de Mafèrinyah, Hôpital Préfectoral de Forecariah,
343 Community leaders in Maferyniah and Forecariah, Guinea; UCRC study team members, Centre de Santé
344 Communautaire de Bakorobabougou, Centres de Santé de Reference Commune VI, Direction Générale
345 de la Santé et de l'Hygiène Publique, Direction Régionale de la Santé of Bamako and Koulikoro,
346 Community partners, Mali; Diane Griffin (deceased) and Jessica Rubens, Johns Hopkins University. We
347 are grateful to Sanofi-Pasteur for contributions.

348 **References**

- 349 1. Frenkel, L.D., *The global burden of vaccine-preventable infectious diseases in children*
350 *less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?*
351 *Allergy Asthma Proc*, 2021. **42**(5): p. 378-385.

- 352 2. Vittrup, D.M., et al., *Measles-mumps-rubella vaccine at 6 months of age, immunology,*
353 *and childhood morbidity in a high-income setting: study protocol for a randomized*
354 *controlled trial*. *Trials*, 2020. **21**(1): p. 1015.
- 355 3. WHO. *WHO. Measles fact sheet*. 2023 [cited 2024 February 7]; Available from:
356 <https://www.who.int/en/news-room/fact-sheets/detail/measles>.
- 357 4. WHO. *A 30-fold rise of measles cases in 2023 in the WHO European region warrants*
358 *urgent action*. 2023; Available from: [https://www.who.int/europe/news/item/14-12-2023-](https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action)
359 [a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-](https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action)
360 [action](https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action).
- 361 5. Patel MK, G.J., Alexander JP Jr., et al. *Progress toward regional measles elimination —*
362 *Worldwide, 2000–2019*. *MMWR Morb Mortal Wkly Rep* 2020;69:1700–1705 2020;
363 Available from: <http://dx.doi.org/10.15585/mmwr.mm6945a6>.
- 364 6. WHO. *African region reported cases of vaccine-preventable diseases (VPDs)*. 2023;
365 Available from: [https://immunizationdata.who.int/global/wiise-detail-page/vaccination-](https://immunizationdata.who.int/global/wiise-detail-page/vaccination-schedule-for-country_name?DISEASECODE=&TARGETPOP_GENERAL=)
366 [schedule-for-country_name?DISEASECODE=&TARGETPOP_GENERAL=](https://immunizationdata.who.int/global/wiise-detail-page/vaccination-schedule-for-country_name?DISEASECODE=&TARGETPOP_GENERAL=)
- 367 7. Diallo, M., et al., *Comparing vaccination coverage before and during COVID-19*
368 *pandemic in children under one year in the health district of commune V in Bamako,*
369 *Mali*. *BMC Pediatr*, 2023. **23**(1): p. 599.
- 370 8. WHO. *Global health observatory data repository*. 2023; Available from:
371 <https://apps.who.int/gho/data/node.main.A826>.
- 372 9. Griffin, D.E., *Measles vaccine*. *Viral Immunol*, 2018. **31**(2): p. 86-95.
- 373 10. SeyedAlinaghi, S., et al., *Impact of COVID-19 pandemic on routine vaccination coverage*
374 *of children and adolescents: A systematic review*. *Health Sci Rep*, 2022. **5**(2): p. e00516.

- 375 11. Shet, A., et al., *Impact of the SARS-CoV-2 pandemic on routine immunisation services:*
376 *evidence of disruption and recovery from 170 countries and territories.* Lancet Glob
377 Health, 2022. **10**(2): p. e186-e194.
- 378 12. Truelove, S.A., W.J. Moss, and J. Lessler, *Mitigating measles outbreaks in West Africa*
379 *post-Ebola.* Expert Rev Anti Infect Ther, 2015. **13**(11): p. 1299-301.
- 380 13. Grundy, J. and B.A. Biggs, *The impact of conflict on immunisation coverage in 16*
381 *countries.* Int J Health Policy Manag, 2019. **8**(4): p. 211-221.
- 382 14. Jawad, M., et al., *Implications of armed conflict for maternal and child health: A*
383 *regression analysis of data from 181 countries for 2000-2019.* PLoS Med, 2021. **18**(9): p.
384 e1003810.
- 385 15. Behrens, L., J.D. Cherry, and U. Heininger, *The susceptibility to other infectious diseases*
386 *following Measles during a three year observation period in Switzerland.* Pediatr Infect
387 Dis J, 2020. **39**(6): p. 478-482.
- 388 16. Bühl, D., et al., *Specifically increased rate of infections in children post measles in a high*
389 *resource setting.* Front Pediatr, 2022. **10**: p. 896086.
- 390 17. Gadroen, K., et al., *Impact and longevity of measles-associated immune suppression: a*
391 *matched cohort study using data from the THIN general practice database in the UK.*
392 BMJ Open, 2018. **8**(11): p. e021465.
- 393 18. Le, N.T.H., et al., *Biphasic pattern in the effect of severe measles infection; the difference*
394 *between additive and multiplicative scale.* BMC Infect Dis, 2021. **21**(1): p. 1249.
- 395 19. Sato, R. and M. Haraguchi, *Effect of measles prevalence and vaccination coverage on*
396 *other disease burden: evidence of measles immune amnesia in 46 African countries.* Hum
397 Vaccin Immunother, 2021. **17**(12): p. 5361-5366.

- 398 20. Aaby, P., et al., *The survival benefit of measles immunization may not be explained*
399 *entirely by the prevention of measles disease: a community study from rural Bangladesh.*
400 *Int J Epidemiol*, 2003. **32**(1): p. 106-16.
- 401 21. Aaby, P., et al., *Non-specific beneficial effect of measles immunisation: analysis of*
402 *mortality studies from developing countries.* *Bmj*, 1995. **311**(7003): p. 481-5.
- 403 22. Higgins, J.P., et al., *Association of BCG, DTP, and measles containing vaccines with*
404 *childhood mortality: systematic review.* *BMJ*, 2016. **355**: p. i5170.
- 405 23. Mina, M.J., *Measles, immune suppression and vaccination: direct and indirect*
406 *nonspecific vaccine benefits.* *J Infect*, 2017. **74 Suppl 1**: p. S10-s17.
- 407 24. Sørup, S., et al., *Live vaccine against measles, mumps, and rubella and the risk of*
408 *hospital admissions for nontargeted infections.* *JAMA*, 2014. **311**(8): p. 826-35.
- 409 25. Griffin, D., *Measles immunity and immunosuppression.* *Curr Opin Virol*, 2021. **46**.
- 410 26. Mina, M.J., et al., *Measles virus infection diminishes preexisting antibodies that offer*
411 *protection from other pathogens.* *Science*, 2019. **366**(6465): p. 599-606.
- 412 27. Petrova, V.N., et al., *Incomplete genetic reconstitution of B cell pools contributes to*
413 *prolonged immunosuppression after measles.* *Sci Immunol*, 2019. **4**(41).
- 414 28. Laksono, B.M., et al., *Studies into the mechanism of measles-associated immune*
415 *suppression during a measles outbreak in the Netherlands.* *Nat Commun*, 2018. **9**(1): p.
416 4944.
- 417 29. Cox, R.M., et al., *Therapeutic mitigation of measles-like immune amnesia and*
418 *exacerbated disease after prior respiratory virus infections in ferrets.* *Nat Commun*,
419 2024. **15**(1): p. 1189.

- 420 30. WHO. *Control of neglected tropical diseases: Rabies, epidemiology and burden of*
421 *disease: Global burden of dog-transmitted human rabies*. . [cited 2024 February 7];
422 Available from: [https://www.who.int/teams/control-of-neglected-tropical-](https://www.who.int/teams/control-of-neglected-tropical-diseases/rabies/epidemiology-and-burden)
423 [diseases/rabies/epidemiology-and-burden](https://www.who.int/teams/control-of-neglected-tropical-diseases/rabies/epidemiology-and-burden). .
- 424 31. WHO. *WHO expert consultation on rabies: WHO-TRS-1012*. 2018 [cited 2024 February
425 7]; Available from: <https://www.who.int/publications/i/item/WHO-TRS-1012>.
- 426 32. CDC. *Rabies Postexposure Prophylaxis (PEP)*. 2022; Available from:
427 https://www.cdc.gov/rabies/medical_care/index.html#:~:text=Postexposure%20prophyla
428 [xis%20\(PEP\)%20consists%20of,3%2C%207%2C%20and%2014](https://www.cdc.gov/rabies/medical_care/index.html#:~:text=Postexposure%20prophylaxis%20(PEP)%20consists%20of,3%2C%207%2C%20and%2014).
- 429 33. WHO. *Measles*. 2023; Available from: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/measles)
430 [sheets/detail/measles](https://www.who.int/news-room/fact-sheets/detail/measles).
- 431 34. Woo, G.K., et al., *Comparison of laboratory diagnostic methods for measles infection*
432 *and identification of measles virus genotypes in Hong Kong*. J Med Virol, 2010. **82**(10):
433 p. 1773-81.
- 434 35. WHO, *Manual for the laboratory-based surveillance of measles, rubella, and*
435 *congenital rubella syndrome*, in *Chapter 3. Clinical specimens for the laboratory confirmation*
436 *and molecular epidemiology of*
437 *measles, rubella, and CRS*.
- 438 36. CDC *Pattern of wild test results among patients with wild measles infection, by day from*
439 *rash onset and type of sampling method used-WHO Measles and Rubella laboratory*
440 *network*. 2008.
- 441 37. WHO *Measles and rubella laboratory network: 2007 meeting on use of alternative*
442 *sampling techniques for surveillance*. 2008. 225 - 232.

- 443 38. Credle, J.J., et al., *Unbiased discovery of autoantibodies associated with severe COVID-*
444 *19 via genome-scale self-assembled DNA-barcoded protein libraries.* Nat Biomed Eng,
445 2022. 6(8): p. 992-1003.
446




Figure 2